tetano
Editor, Senior Moderator
Virology. 2017 Jun 13;509:82-89. doi: 10.1016/j.virol.2017.06.001. [Epub ahead of print]
[h=1]Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge.[/h] Deng L[SUP]1[/SUP], Kim JR[SUP]2[/SUP], Chang TZ[SUP]3[/SUP], Zhang H[SUP]2[/SUP], Mohan T[SUP]1[/SUP], Champion JA[SUP]3[/SUP], Wang BZ[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Currently marketed influenza vaccines only confer protection against matching influenza virus strains. The influenza A composition of these vaccines needs to be annually updated. Vaccines that target conserved epitopes of influenza viruses would in principle offer broad cross-protection against influenza A viruses. In our study, we investigated the specific immune responses and protective efficacy of protein nanoparticles based on fusion proteins of flagellin carrier linked to conserved influenza epitopes. We designed fusion proteins by replacing the hyperimmunogenic region of flagellin (FliC) with four tandem copies of the ectodomain of matrix protein 2 (f4M2e), H1 HA2 domain (fHApr8) or H3 HA2 domain (fHAaichi). Protein nanoparticles fabricated from these fusion proteins by using DTSSP crosslinking retained Toll-like receptor 5 agonist activity of FliC. Intranasal immunization with f4M2e, f4M2e/fHApr8 or f4M2e/fHAaichi nanoparticles induced vaccine antigen-specific humoral immune responses. It was also found that the incorporation of the H1 HA2 domain into f4M2e/fHApr8 nanoparticles boosted M2e specific antibody responses. Immunized mice were fully protected against lethal doses of virus challenge.
Copyright ? 2017 Elsevier Inc. All rights reserved.
[h=4]KEYWORDS:[/h] Flagellin; Hemagglutinin; Influenza; Matrix protein 2 ectodomain; Nanoparticle; Vaccine
PMID: 28622575 DOI: 10.1016/j.virol.2017.06.001
[h=1]Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge.[/h] Deng L[SUP]1[/SUP], Kim JR[SUP]2[/SUP], Chang TZ[SUP]3[/SUP], Zhang H[SUP]2[/SUP], Mohan T[SUP]1[/SUP], Champion JA[SUP]3[/SUP], Wang BZ[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Currently marketed influenza vaccines only confer protection against matching influenza virus strains. The influenza A composition of these vaccines needs to be annually updated. Vaccines that target conserved epitopes of influenza viruses would in principle offer broad cross-protection against influenza A viruses. In our study, we investigated the specific immune responses and protective efficacy of protein nanoparticles based on fusion proteins of flagellin carrier linked to conserved influenza epitopes. We designed fusion proteins by replacing the hyperimmunogenic region of flagellin (FliC) with four tandem copies of the ectodomain of matrix protein 2 (f4M2e), H1 HA2 domain (fHApr8) or H3 HA2 domain (fHAaichi). Protein nanoparticles fabricated from these fusion proteins by using DTSSP crosslinking retained Toll-like receptor 5 agonist activity of FliC. Intranasal immunization with f4M2e, f4M2e/fHApr8 or f4M2e/fHAaichi nanoparticles induced vaccine antigen-specific humoral immune responses. It was also found that the incorporation of the H1 HA2 domain into f4M2e/fHApr8 nanoparticles boosted M2e specific antibody responses. Immunized mice were fully protected against lethal doses of virus challenge.
Copyright ? 2017 Elsevier Inc. All rights reserved.
[h=4]KEYWORDS:[/h] Flagellin; Hemagglutinin; Influenza; Matrix protein 2 ectodomain; Nanoparticle; Vaccine
PMID: 28622575 DOI: 10.1016/j.virol.2017.06.001